These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9228993)

  • 1. Ibopamine and survival in severe congestive heart failure: PRIME II.
    Girbes AR; Zijlstra JG
    Lancet; 1997 Jul; 350(9071):147-8. PubMed ID: 9228993
    [No Abstract]   [Full Text] [Related]  

  • 2. Ibopamine and survival in severe congestive heart failure: PRIME II.
    Massel D
    Lancet; 1997 Jul; 350(9071):147. PubMed ID: 9228992
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators.
    Hampton JR; van Veldhuisen DJ; Kleber FX; Cowley AJ; Ardia A; Block P; Cortina A; Cserhalmi L; Follath F; Jensen G; Kayanakis J; Lie KI; Mancia G; Skene AM
    Lancet; 1997 Apr; 349(9057):971-7. PubMed ID: 9100622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitored long-term treatment with ibopamine in patients suffering from severe congestive heart failure.
    Avanzini Z; Bellogini GC; Brusoni B; Ciampani N; Dei Cas L; Gazzola U; Maggi GC; Mangiavacchi M; Metra M; Pinca L
    Arzneimittelforschung; 1986 Feb; 36(2A):394-7. PubMed ID: 3707656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk factors for dying among ibopamine users].
    Vandenbroucke JP
    Ned Tijdschr Geneeskd; 1999 Jul; 143(31):1631-2. PubMed ID: 10488378
    [No Abstract]   [Full Text] [Related]  

  • 6. Hemodynamic evaluation of ibopamine in patients with refractory congestive heart failure.
    Humar F; Morgera T; Maras P; Camerini F
    Arzneimittelforschung; 1986 Feb; 36(2A):360-2. PubMed ID: 3707650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRIME II (Second Prospective Randomized Study of Ibupamine on Mortality and Efficacy): another disappointment in heart failure therapy.
    Hampton JR
    Eur Heart J; 1997 Oct; 18(10):1519-20. PubMed ID: 9347257
    [No Abstract]   [Full Text] [Related]  

  • 8. Multicenter study on the clinical efficacy of chronic ibopamine administration.
    Dei Cas L; Barilli AC; Metra M; Fracalossi C; Lomanto B; Santambrogio S; Pinca L; Longhini C; Cavicchi E; Maggi GC
    Arzneimittelforschung; 1986 Feb; 36(2A):383-5. PubMed ID: 3707655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk factors for dying among ibopamine users].
    de Graeff PA; Elferink AJ; Lekkerkerker JF
    Ned Tijdschr Geneeskd; 1999 May; 143(21):1114-5. PubMed ID: 10368748
    [No Abstract]   [Full Text] [Related]  

  • 10. A survey of 311 patients receiving ibopamine mainly during hospital treatment for severe congestive heart failure.
    Ferrari V; Sher D; Marchetti G
    Arzneimittelforschung; 1986 Feb; 36(2A):398-405. PubMed ID: 3707657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of proarrhythmic effects of ibopamine in patients with congestive heart failure.
    Caponnetto S; Terrachini V; Canale C; Bruzzone F; Licciardello L; Marchetti GV
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S104-10. PubMed ID: 2483435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemodynamic evaluation of ibopamine in severe congestive heart failure.
    Reffo GC; Turrin M; Gabellini A; Forattini C
    Eur J Clin Pharmacol; 1984; 26(1):19-22. PubMed ID: 6714289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibopamine post-marketing surveillance. First report from a parallel-cohorts survey ongoing since April 1st, 1985.
    Sher D; Ferrari V
    Arzneimittelforschung; 1987 Jul; 37(7A):873-900. PubMed ID: 3675684
    [No Abstract]   [Full Text] [Related]  

  • 14. Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group.
    Brouwer J; van Veldhuisen DJ; Man in 't Veld AJ; Dunselman PH; Boomsma F; Haaksma J; Lie KI
    J Am Coll Cardiol; 1995 Oct; 26(4):983-90. PubMed ID: 7560628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of ibopamine on heart rate and arrhythmic pattern in patients with congestive heart failure. A double-blind multicentre study.
    G Ital Cardiol; 1989 Jan; 19(1):71-80. PubMed ID: 2663585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of ibopamine therapy in congestive heart failure. Ibopamine cohort study: baseline and 1-year results.
    Sher D; Licciardello L; Ferrari V; Sirtori F; Cesana B
    Arzneimittelforschung; 1991 Apr; 41(4):402-9. PubMed ID: 1859514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ibopamine: the message, the messenger and the need of pharmacoepidemiological research].
    Stricker BH; Feenstra J; Ottervanger JP
    Ned Tijdschr Geneeskd; 1996 Apr; 140(15):848-50. PubMed ID: 8668281
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of mild heart failure: the place of diuretics and ibopamine.
    Van Veldhuisen DJ
    Eur Heart J; 1997 May; 18(5):712-4. PubMed ID: 9152639
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of ibopamine treatment in patients with advanced heart failure: purpose of a new therapeutic scheme with multiple daily administrations.
    Dei Cas L; Metra M; Nodari S; Visioli O
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S111-7. PubMed ID: 2483436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hemodynamic effects induced by the combined administration of sodium nitroprusside and ibopamine in patients with congestive heart decompensation].
    Dei Cas L; Giunti G; Faggiano P; Fappani A; Ferrari R; La Canna G; Riva S; Zanini R
    Cardiologia; 1985 Mar; 30(3):205-11. PubMed ID: 4064071
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.